Compare SOHU & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOHU | CCCC |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.6M | 350.6M |
| IPO Year | 2018 | 2020 |
| Metric | SOHU | CCCC |
|---|---|---|
| Price | $12.54 | $3.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $19.50 | $12.86 |
| AVG Volume (30 Days) | 84.9K | ★ 2.0M |
| Earning Date | 11-16-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.46 | N/A |
| P/E Ratio | $1.16 | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $11.61 | $1.69 |
| 52 Week High | $17.30 | $5.17 |
| Indicator | SOHU | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 39.14 | 44.23 |
| Support Level | $12.41 | $2.88 |
| Resistance Level | $13.71 | $3.20 |
| Average True Range (ATR) | 0.36 | 0.22 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 25.51 | 54.54 |
Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.